Related Experiment Video
Updated: Feb 5, 2026

A General Method for Evaluating Incubation of Sucrose Craving in Rats
Published on: November 4, 2011
Evaluation of samidorphan, a μ-opioid antagonist, in a drug discrimination assay in rats
Mario P Sgro1, Deah L Modlin1, Daniel R Deaver2
1Department of Biology, Formerly of Covance Laboratories, Greenfield, Indiana.
Abstract:
Preclinical Research & Development Background: Samidorphan, a μ-opioid receptor antagonist, is in clinical development for central nervous system related diseases. The discriminative stimulus effects of samidorphan were assessed in rats trained to discriminate the effects of a known morphinan of abuse, morphine, from that of saline.
Methods:
Escalating doses of samidorphan were substituted for morphine and rats were allowed to respond on two levers for food reward. Doses of samidorphan were chosen based on other pharmacodynamic assays in which samidorphan blocked the effects of morphine (such as blocking analgesia in a hot plate test; data not shown). In addition, a pharmacokinetic study was conducted to determine if these doses would reflect predicted exposure levels that translate to human equivalent doses.
Results:
Rats discriminating morphine from vehicle responded predominantly on the vehicle lever after receiving samidorphan. In addition, samidorphan was rapidly absorbed, and plasma concentrations of the doses tested in this study bracket therapeutically relevant concentrations.
Conclusions:
In summary, samidorphan produced saline-like behavioral responses over a wide dose range.
Related Concept Videos
Drugs Affecting GI Tract Motility: Opioids as Antidiarrheal Agents
Opioids, widely used antidiarrheal agents, mitigate diarrhea by slowing down...
Stereotypes, Prejudice, and Discrimination
Drug-Receptor Interaction: Antagonist
Antagonists can be classified as competitive or noncompetitive based on their...
Antiepileptic Drugs: Glutamate Antagonists
Opioid Analgesics: Synthetic and Semisynthetic Opioids
Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...

